rine Liver-Type Fatty-Acid Binding Protein (L-FABP); a Novel Biomarker for Predicting Short-term Mortality in Hospitalized Cirrhotic Patients

Completed

• Conditions: Acute kidney injury in patients with cirrhosis requiring hospitalization; cirrhosis; acute kidney injury; novel biomarker; Liver type Fatty Acid Binding Protein; Neutrophil Gelatinase Associated Lipocalin

• Registration Number: TCTR20211121002
• Lead Sponsor: Ratchadapisek Sompoch Funding, Chulalongkorn University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2019-11-30
• Study Start: 2021-11-21
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 139

Inclusion Criteria

1. Known diagnosis of cirrhosis
2. Presence of risk of acute kidney injury, including gastrointestinal bleeding, bacterial infection, diarrhea, vomiting, poor intake, large-volume paracentesis, excessive diuretics usage, taking nephrotoxic drugs, and acute decompensation

Exclusion Criteria

1. Prior liver or kidney transplantation
2. End-stage renal disease with renal replacement therapy at the time of enrollment
3. Acute interstitial nephritis
4. Acute glomerulonephritis
5. Post-renal acute kidney injury
4. Current use of immunosuppressive agents other than treatment of severe alcoholic hepatitis
5. Severe extrahepatic disease
6. Pregnancy

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Acute kidney injury At 7 days after hospitalization Serum creatinine

Secondary Outcome Measures

Name	Time	Method
Mortality At 28 days after hospitalization Death